Compare NAAS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAAS | CELU |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 34.5M |
| IPO Year | 2017 | N/A |
| Metric | NAAS | CELU |
|---|---|---|
| Price | $3.23 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 23.5K | ★ 71.7K |
| Earning Date | 03-31-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $21,817,052.00 | ★ $40,578,000.00 |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.96 | $1.00 |
| 52 Week High | $40.32 | $4.35 |
| Indicator | NAAS | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 46.91 |
| Support Level | $3.01 | $1.25 |
| Resistance Level | $3.30 | $1.33 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 50.43 | 94.31 |
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.